Cumberland Pharmaceuticals (CPIX) Projected to Release Quarterly Earnings on Tuesday

Key Points

• Cumberland Pharmaceuticals is expected to report Q3 2026 results before the market opens on November 3. Analysts forecast a loss of $0.13 per share and revenue of $8.50 million.
• The company’s previous quarter missed expectations, reporting a $0.20 per-share loss versus the forecasted $0.13 loss, along with a negative net margin of 34.40%.
• CPIX shares opened at $4.35, well below their 50-day moving average of $7.36, while the stock carries a consensus Sell rating and a $65.16 million market capitalization.

Cumberland Pharmaceuticals (NASDAQ:CPIX - Get Free Report) is anticipated to announce its Q3 2026 results before the market opens on Tuesday, November 3rd. Analysts expect the company to announce earnings of ($0.13) per share and revenue of $8.50 million for the quarter. Parties can check the company's upcoming Q3 2026 earnings report for the latest details on the call scheduled for Tuesday, November 3, 2026 at 4:30 PM ET.

Cumberland Pharmaceuticals (NASDAQ:CPIX - Get Free Report) last released its quarterly earnings data on Tuesday, August 4th. The specialty pharmaceutical company reported ($0.20) EPS for the quarter, missing analysts' consensus estimates of ($0.13) by ($0.07). Cumberland Pharmaceuticals had a negative return on equity of 28.81% and a negative net margin of 34.40%. The business had revenue of $0.17 million for the quarter, compared to the consensus estimate of $8.50 million.

Cumberland Pharmaceuticals Price Performance

Cumberland Pharmaceuticals stock opened at $4.35 on Tuesday. The stock has a fifty day moving average price of $7.36 and a two-hundred day moving average price of $5.53. Cumberland Pharmaceuticals has a 52-week low of $1.85 and a 52-week high of $9.28. The firm has a market capitalization of $65.16 million, a P/E ratio of -6.13 and a beta of 0.06.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a "sell (d-)" rating on shares of Cumberland Pharmaceuticals in a research note on Monday, September 21st. One research analyst has rated the stock with a Sell rating. According to MarketBeat, the stock presently has a consensus rating of "Sell".

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company headquartered in Nashville, Tennessee. The company develops, acquires and commercializes prescription medicines, with a focus on products that address unmet needs in critical care, gastroenterology, pain management and other specialty areas.

Its portfolio has included Caldolor (ibuprofen injection), Acetadote (acetylcysteine injection), Kristalose (lactulose for oral solution), Vaprisol (conivaptan hydrochloride injection) and Omeclamox-Pak, a treatment for certain Helicobacter pylori infections.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.